Bifogade filer
PDF
Kurs
-2,14%
Likviditet
0,18 MSEK
Kalender
| Tid* | ||
| 2025-02-21 | 08:30 | Bokslutskommuniké 2024 |
| 2024-12-19 | - | Extra Bolagsstämma 2024 |
| 2024-11-29 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-05 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2024-06-04 | - | Årsstämma |
| 2024-04-26 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-16 | - | Bokslutskommuniké 2023 |
| 2023-11-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-10-02 | - | Extra Bolagsstämma 2023 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-04-28 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-11 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-12 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2022-05-04 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-11 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2021-04-28 | - | Årsstämma |
| 2021-04-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-13 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-13 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2020-05-12 | - | Årsstämma |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-25 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-16 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-17 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-26 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2019-04-25 | - | Årsstämma |
| 2019-02-13 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-22 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2018-03-21 | - | Årsstämma |
| 2018-02-06 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-30 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The first patient in the AcuCort Phase IV study ZEQ001 has been assigned the oral film Zeqmelit®. The purpose of the study is to enhance marketing with practical experience from doctors and patients in connection with the launch in the Nordic region.
The study will run concurrently with the Nordic market launch. In the study, allergy patients are assigned the company's oral film Zeqmelit® for use when the need for treatment for acute allergic reactions arises.
The goal of the study, which is an open-label non-randomized low-intervention study, is to obtain valuable data on the use of Zeqmelit® from patients who have previously been prescribed corticosteroids in tablet form for self-treatment during acute allergic reactions.
"We are reaching a very important milestone now as the first patient is using Zeqmelit. The initiation of the study supports the ongoing commercialization efforts and the upcoming market launch in the Nordic region," says Jonas Jönmark, CEO of AcuCort.
The study includes about 50 allergy patients who will be added continuously over the next six months.
"We look forward to publishing the study results at the end of the year. We believe it will be an important part of the marketing of Zeqmelit® as we will be able to communicate real experiences from patients and doctors," says Jonas Jönmark."
Jonas Jönmark, CEO AcuCort AB
Tel: +46 70 3655400
Email: jonas.jonmark@acucort.se